Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022)
Travere Therapeutics posted quarterly Liabilities from Discontinued Operations of 7000000.0 for Q4 2022.
Travere Therapeutics (TVTX) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 7000000.0 in Q4 2022.
- For the quarter ending Q4 2022, Liabilities from Discontinued Operations changed N/A year-over-year to 7000000.0; the trailing twelve-month figure through Dec 2022 stood at 7000000.0 (changed N/A YoY), and the FY2022 full-year result was 7000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q4 2022 stood at 7000000.0.
- Across five years, Liabilities from Discontinued Operations topped out at 7000000.0 in Q4 2022 and bottomed at 7000000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 7.00 Mn |
| Dec 31, 2022 | 7.00 Mn |